The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. director Vinokur Yehonatan Zalman has filed an initial ownership report of the company’s ordinary shares. The filing shows he holds both fully vested and restricted ordinary shares granted under the Polyrizon Ltd. Amended and Restated Equity Incentive Plan.
According to the disclosure, 521 ordinary shares are already vested, while 3,125 restricted ordinary shares are scheduled to vest in six equal quarterly installments beginning on March 31, 2026, subject to his continued service. Additional restricted ordinary shares are set to vest in seven equal quarterly installments beginning on April 30, 2026, also contingent on continued service.
The filing notes that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, equity awarded under the plan must be registered in the name of a trustee, which affects how these holdings are formally recorded.
Polyrizon Ltd. director Carmel Liron filed an initial ownership report showing restricted ordinary share awards rather than new market transactions. Liron holds 2 restricted ordinary shares that vest in 7 equal quarterly installments beginning on April 30, 2026, subject to continued service. An additional 4,167 ordinary shares are reported, of which 1,042 are already vested and 3,125 are restricted shares vesting in 6 equal quarterly installments starting March 31, 2026, also contingent on continued service. Certain equity awards are held through a trustee to qualify for Israeli Section 102 tax benefits.
Polyrizon Ltd. Chief Technology Officer Tidhar Turgeman filed an initial ownership report showing direct holdings of ordinary shares and employee options. He holds 18 restricted ordinary shares, with 5 already vested and 13 vesting in 8 equal monthly installments on a quarterly basis beginning on March 30, 2026, subject to continued service. He also holds 20,417 restricted ordinary shares, with 2,917 vested and 17,500 vesting in 6 equal quarterly installments beginning on March 31, 2026, subject to continued service. In addition, he holds options over 12, 23 and 7 ordinary shares at exercise prices of 1018.3000, 1700.3000 and 26.1000, expiring between August 30, 2026 and November 29, 2028. Certain securities are held through a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
Polyrizon Ltd. director Adler Oz has filed an initial ownership report showing holdings of the company’s ordinary shares, mainly in the form of restricted stock awards. One grant covers 100 ordinary shares, of which 66 are vested and 34 will vest in eight equal monthly installments on a quarterly basis beginning on March 30, 2026, subject to continued service. A second grant covers 23,042 ordinary shares, with 3,292 already vested and 19,750 scheduled to vest in six equal quarterly installments beginning on March 31, 2026. Certain shares are held through a trustee structure designed to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
Polyrizon Ltd. director and Chief Executive Officer Tomer Izraeli filed an initial ownership report showing his equity position in the company. He holds options to purchase ordinary shares, covering 5 and 83 underlying shares at exercise prices of 1699.3000 and 1700.3000 per share, expiring in 2026 and 2028. He also directly holds ordinary shares, including 53 restricted shares with 17 already vested and 36 scheduled to vest in eight equal quarterly installments beginning on March 30, 2026, and 35,780 restricted shares with 5,780 vested and 30,000 vesting in six equal quarterly installments beginning on March 31, 2026, all subject to his continued service.
Polyrizon Ltd. Chief Financial Officer BenYosef Nir has filed an initial statement of beneficial ownership, detailing his current equity position in the company. He holds an option to purchase 2 ordinary shares at an exercise price of 1699.3000 per share, expiring on December 26, 2026, alongside direct holdings of ordinary shares.
Footnotes explain that portions of these ordinary shares are restricted and vest over time. One grant vests in 8 equal monthly installments on a quarterly basis beginning on March 30, 2026, while another includes 104 already vested shares and 625 restricted shares vesting in 6 equal quarterly installments beginning on March 31, 2026, all subject to his continued service and structured to qualify for Israeli Section 102 tax benefits through a trustee arrangement.
Polyrizon Ltd. reports that it has signed an agreement with a leading global preclinical contract research organization to support its clinical development program for intranasal hydrogel-based medical devices. The CRO will run a package of biocompatibility studies under ISO 10993 standards and GLP requirements.
The studies are expected to begin in the second quarter of 2026 and are described as a key milestone on Polyrizon’s regulatory path toward starting clinical trials planned for later this year. The program will test cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity to help demonstrate product safety before human studies.
Polyrizon Ltd. filing reports that Eli Zamir holds beneficial ownership of the issuer's Ordinary Shares at a level of 5% or less as of 12/31/2025. The filing lists the issuer's principal office in Raanana, Israel, and is signed on 03/16/2026.
Polyrizon Ltd. reported that it has successfully produced a Good Manufacturing Practice (GMP) batch of clinical trial material for its lead intranasal product candidate, working with Eurofins CDMO AmatsiAquitaine S.A.S. This batch will supply a planned clinical study in the United States later this year.
The GMP lot follows two earlier development batches that showed consistent manufacturing performance and product stability, supporting a robust, reproducible process. Polyrizon views this manufacturing milestone as an important step in advancing its clinical development strategy and its intranasal technology platform aimed at protecting against airborne allergens and viruses.
Polyrizon Ltd. received an amended Schedule 13G/A from L.I.A. Pure Capital Ltd. reporting beneficial ownership of 5 percent or less of the company's ordinary shares.
The filing references the cover pages for details on voting and dispositive powers and identifies the reporting person and its Israeli address and citizenship.